W. Hiddemann

2.7k total citations
100 papers, 2.0k citations indexed

About

W. Hiddemann is a scholar working on Oncology, Hematology and Molecular Biology. According to data from OpenAlex, W. Hiddemann has authored 100 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Oncology, 29 papers in Hematology and 25 papers in Molecular Biology. Recurrent topics in W. Hiddemann's work include Acute Myeloid Leukemia Research (21 papers), Lymphoma Diagnosis and Treatment (17 papers) and Chronic Lymphocytic Leukemia Research (15 papers). W. Hiddemann is often cited by papers focused on Acute Myeloid Leukemia Research (21 papers), Lymphoma Diagnosis and Treatment (17 papers) and Chronic Lymphocytic Leukemia Research (15 papers). W. Hiddemann collaborates with scholars based in Germany, United States and Switzerland. W. Hiddemann's co-authors include Bernhard Wörmann, Claudia R. Binder, Th. Büchner, Lutz Binder, Christian Buske, Michael Unterhalt, Claudia Schoch, Michaela Feuring‐Buske, Stephanie Könemann and B. Wörmann and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

W. Hiddemann

98 papers receiving 1.9k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
W. Hiddemann Germany 25 758 731 633 402 387 100 2.0k
June‐Won Cheong South Korea 29 994 1.3× 1.0k 1.4× 625 1.0× 417 1.0× 581 1.5× 182 2.7k
Tanya Trippett United States 24 380 0.5× 580 0.8× 655 1.0× 380 0.9× 235 0.6× 79 1.9k
Pierre Stryckmans Belgium 26 1.1k 1.5× 750 1.0× 678 1.1× 382 1.0× 827 2.1× 97 2.5k
Diane E. Cole United States 24 359 0.5× 661 0.9× 912 1.4× 584 1.5× 554 1.4× 55 2.2k
A Tobler Switzerland 26 550 0.7× 1.0k 1.4× 806 1.3× 370 0.9× 394 1.0× 70 2.3k
Akil Merchant United States 24 818 1.1× 1.5k 2.0× 836 1.3× 282 0.7× 226 0.6× 84 2.5k
Rocco Piazza Italy 26 874 1.2× 761 1.0× 447 0.7× 210 0.5× 659 1.7× 137 2.2k
Lewis Cohen United States 19 332 0.4× 423 0.6× 511 0.8× 279 0.7× 250 0.6× 41 1.9k
George E. Georges United States 29 1.7k 2.2× 597 0.8× 585 0.9× 436 1.1× 641 1.7× 106 3.1k
Lydia Campos France 29 1.7k 2.3× 1.7k 2.3× 912 1.4× 207 0.5× 515 1.3× 106 3.3k

Countries citing papers authored by W. Hiddemann

Since Specialization
Citations

This map shows the geographic impact of W. Hiddemann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by W. Hiddemann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites W. Hiddemann more than expected).

Fields of papers citing papers by W. Hiddemann

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by W. Hiddemann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by W. Hiddemann. The network helps show where W. Hiddemann may publish in the future.

Co-authorship network of co-authors of W. Hiddemann

This figure shows the co-authorship network connecting the top 25 collaborators of W. Hiddemann. A scholar is included among the top collaborators of W. Hiddemann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with W. Hiddemann. W. Hiddemann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hutter, Grit, et al.. (2016). Mode of action of different PI3K-inhibitors in mantle cell lymphoma. Haematologica. 1 indexed citations
2.
Aktan, Meryem, Anna Schuh, Peter Johansson, et al.. (2015). Rituximab in combination with bendamustine or chlorambucil for the treatment of chronic lymphocytic leukemia: primary results from the randomised phase IIIb MABLE study. Leukemia & lymphoma. 56. 149–149. 10 indexed citations
3.
Greif, Philipp A., Nikola P. Konstandin, Klaus H. Metzeler, et al.. (2012). RUNX1 mutations in cytogenetically normal acute myeloid leukemia are associated with a poor prognosis and up-regulation of lymphoid genes. Haematologica. 97(12). 1909–1915. 66 indexed citations
4.
Wittmann, Marc, et al.. (2010). Preoccupation with death as predictor of psychological distress in patients with haematologic malignancies. European Journal of Cancer Care. 20(3). 403–411. 14 indexed citations
5.
Kohlmann, Alexander, Claudia Schoch, Martin Dugas, et al.. (2005). New insights into MLL gene rearranged acute leukemias using gene expression profiling: shared pathways, lineage commitment, and partner genes. Leukemia. 19(6). 953–964. 66 indexed citations
6.
Lenz, Georg, W. Hiddemann, & Martin Dreyling. (2004). The role of fludarabine in the treatment of follicular and mantle cell lymphoma. Cancer. 101(5). 883–893. 30 indexed citations
7.
Kern, Wolfgang, Claudia Schoch, Alexander Kohlmann, et al.. (2003). Multi-genetic basis for prognostication in acute myeloid leukemia with aberrant and prognostically intermediate karyotypes as determined by gene expression profiling. Blood. 102(11). 190. 1 indexed citations
8.
Hiddemann, W.. (2003). Acute leukemias IX : basic research, experimental approaches and novel therapies. Springer eBooks. 2 indexed citations
9.
Stötzer, Oliver, Michael Schleuning, Georg Ledderose, W. Hiddemann, & Hans-Jochen Kölb. (2001). Allogene Transplantation maligner Lymphome. DMW - Deutsche Medizinische Wochenschrift. 126(39). 1062–1069. 1 indexed citations
10.
Schoch, Claudia, et al.. (2001). Gain of an isochromosome 5p:. Cancer Genetics and Cytogenetics. 127(1). 85–88. 12 indexed citations
11.
Stemmler, Hans‐Joachim, Mahsa Malekmohammadi, Roswitha Forstpointner, et al.. (2001). Weekly docetaxel (Taxotere®) in patients with metastatic breast cancer. Annals of Oncology. 12(10). 1393–1398. 51 indexed citations
12.
Häntschel, M, K. Kevin Pfister, Andreas Jordan, et al.. (2000). Hsp70 plasma membrane expression on primary tumor biopsy material and bone marrow of leukemic patients. Cell Stress and Chaperones. 5(5). 438–438. 120 indexed citations
13.
Mittermüller, J., et al.. (2000). Unklare Laktatazidose bei einem Patienten mit Herzinsuffizienz unter diuretischer Langzeit-Therapie. DMW - Deutsche Medizinische Wochenschrift. 125(41). 1232–1234. 1 indexed citations
14.
Hiddemann, W.. (1998). Acute leukemias VII : experimental approaches and novel therapies. Springer eBooks. 30 indexed citations
15.
Hiddemann, W., et al.. (1997). Acute leukemias V. Experimental approaches and management of refractory disease. Biomedicine & Pharmacotherapy. 51(5). 232–232. 4 indexed citations
16.
Binder, Claudia R., et al.. (1995). Bcl-2 protein expression in breast cancer in relation to established prognostic factors and other clinicopathological variables. Annals of Oncology. 6(10). 1005–1010. 49 indexed citations
17.
Gralow, I., et al.. (1995). Pharmakokinetik des Buprenorphins bei subkutaner Applikation. AINS - Anästhesiologie · Intensivmedizin · Notfallmedizin · Schmerztherapie. 30(7). 412–416. 5 indexed citations
18.
Wörmann, Bernhard, Christoph Reuter, M. Zühlsdorf, Th. Büchner, & W. Hiddemann. (1994). Experimental basis for the use of recombinant human granulocyte-macrophage colony-stimulating factor in patients with acute myeloid leukemia.. PubMed. 21(6 Suppl 16). 39–43. 4 indexed citations
19.
Maschmeyer, Georg, et al.. (1987). Combined Chemotherapy with m-Amsacrine in High-Risk Patients with Acute Non-Lymphocytic Leukemia. Oncology Research and Treatment. 10(1). 18–21. 1 indexed citations
20.
Büchner, Th., et al.. (1978). [Treatment of acute myeloblastic leukemia with cytosine arabinoside combined with daunorubicin or ifosfamide or thioguanine].. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 145–8. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by June‐Won Cheong Breakdown of academic impact, for papers by Tanya Trippett Breakdown of academic impact, for papers by Pierre Stryckmans Breakdown of academic impact, for papers by Diane E. Cole Breakdown of academic impact, for papers by A Tobler Breakdown of academic impact, for papers by Akil Merchant Breakdown of academic impact, for papers by Rocco Piazza Breakdown of academic impact, for papers by Lewis Cohen Breakdown of academic impact, for papers by George E. Georges Breakdown of academic impact, for papers by Lydia Campos
Rankless by CCL
2026